Serial 89Zr-bevacizumab PET in Patients with Neuroendocrine Tumors before and on Everolimus Treatment

A. H. Brouwers, S. J. Van Asselt, S. F. Oosting, J. R. De Jong, M. N. Lub-de Hooge, A. H. H. Bongaerts, Thijs Oude Munnink, H. B. Fiebrich, W. J. Sluiter, T. P. Links, A. M. E. Walenkamp, Liesbeth de Vries

    Research output: Contribution to journalMeeting AbstractAcademic

    Original languageEnglish
    Pages (from-to)259
    Number of pages1
    JournalNeuroendocrinology
    Volume99
    Issue number3-4
    Publication statusPublished - 2014
    Event11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease - Barcelona, Spain
    Duration: 5-Mar-20147-Mar-2014

    Keywords

    • neuroendocrine tumors
    • 89zr-bevacizumab pet
    • vegf-a
    • everolimus
    • biomarker

    Cite this